Douglas R Sutton

US Patent:

7129360, Oct 31, 2006

Filed:

Apr 6, 2004

Appl. No.:

10/818588

Inventors:

Christopher J. Woltermann - Gastonia NC, US
Douglas E. Sutton - Kings Mountain NC, US

Assignee:

FMC Corporation - Philadelphia PA

International Classification:

C07D 211/72

US Classification:

546290, 546298

Abstract:

Substituted alkylmetal reagents such as (trimethylsilylmethyl)lithium are reacted with azaaromatic compounds and/or nitrogen heterocycle compounds to produce functionalized azaaromatic compounds and functionalized nitrogen heterocycle compounds.

US Patent:

7638635, Dec 29, 2009

Filed:

Oct 10, 2006

Appl. No.:

11/539940

Inventors:

Christopher J. Woltermann - Gastonia NC, US
Douglas E. Sutton - Kings Mountain NC, US

Assignee:

FMC Corporation Lithium Division - Philadelphia PA

International Classification:

C07D 213/63

US Classification:

546290, 546298

Abstract:

Substituted alkylmetal reagents such as (trimethylsilylmethyl)lithium are reacted with pyridinic compounds to produce functionalized pyridinic compounds.

US Patent:

20100094017, Apr 15, 2010

Filed:

Dec 18, 2009

Appl. No.:

12/641691

Inventors:

Christopher J. Woltermann - Gastonia NC, US
Douglas E. Sutton - Kings Mountain NC, US

International Classification:

C07D 213/68

US Classification:

546298

Abstract:

Substituted alkylmetal reagents such as (trimethylsilylmethyl)lithium are reacted with pyridinic compounds to produce functionalized pyridinic compounds.

US Patent:

56267983, May 6, 1997

Filed:

Jan 5, 1996

Appl. No.:

8/587813

Inventors:

James A. Schwindeman - Lincolnton NC
Douglas E. Sutton - Kings Mountain NC
Robert C. Morrison - Gastonia NC
Sonia S. Stryker - Charlotte NC

Assignee:

FMC Corporation - Philadelphia PA

International Classification:

C07F 102

US Classification:

260665R

Abstract:

An improved process for producing high purity solutions of aryllithium compounds comprising reacting a particulate alkali metal having a particle size in the range of 10 to 300 microns, with an aryl halide in a normally liquid etheral solvent of the formula ROR. sup. 1, wherein R and R. sup. 1 are selected from the group of alkyl radicals containing from 3 to 6 carbon atoms, in the presence of a Lewis base compound selected from compounds of the formula: R. sup. 2 AR. sup. 3 (R. sup. 4). sub. z and ##STR1## wherein A is selected from oxygen, nitrogen, phosphorus or sulfur; R. sup. 2, R. sup. 3, and R. sup. 4 are selected from alkyl radicals containing from 1 to 6 carbon atoms; R. sup. 5 and R. sup. 6 are independently selected from hydrogen or alkyl radicals containing one to six carbon atoms; y is an integer from 4 to 6; but when A is oxygen or sulfur, z is zero; and when A is nitrogen or phosphorus, z is one, and provided there is a mole ratio of ether to aryl halide of at least 1. 3 to 1 and a mole ratio of Lewis base to aryl halide of from 0. 01 to 0.

US Patent:

56633980, Sep 2, 1997

Filed:

Sep 12, 1996

Appl. No.:

8/711878

Inventors:

James Anthony Schwindeman - Lincolnton NC
Eric John Granger - Charlotte NC
Douglas Earl Sutton - Kings Mountain NC

Assignee:

FMC Corporation - Philadelphia PA

International Classification:

C07F 708
C07F 718

US Classification:

556466

Abstract:

A process for preparing functionalized alkyllithium compounds includes reacting in an inert solvent a protected functionalized alkyl halide with an alkali metal in the presence of a catalytic compound of the formula (RR. sup. 1 R. sup. 2 M. sup. a). sub. y A(R. sup. 3). sub. x wherein R, R. sup. 1 and R. sup. 2 are each independently selected from the group consisting of hydrogen, halogen, alkyl or alkenyl groups containing one to thirteen carbon atoms; R. sup. 3 is independently selected from aryl groups containing 6 to 18 carbon atoms, four to six-membered heterocyclic carbon containing groups containing one to two heteroatoms selected from oxygen, nitrogen and sulfur; hydroxyalkyl, alkoxyalkyl, monoalkylaminoalkyl, dialkylaminoalkyl and dialkylphosphinoalkyl groups containing two to thirteen carbon atoms; M. sup. a is an element selected from Group IVA of the Periodic Table of Elements; A is selected from oxygen, sulfur, nitrogen, and phosphorus; x+y equal the valence of A; and x and y may independently have a value from zero to three.

US Patent:

20210128351, May 6, 2021

Filed:

Jul 16, 2020

Appl. No.:

16/930678

Inventors:

- Parsippany NJ, US
Cary J. Reich - Parsippany NJ, US
Stephen Boyd - Parsippany NJ, US
David Sierra - Parsippany NJ, US
Jose D. Alejandro - Parsippany NJ, US
K. Angela Macfarlane - Parsippany NJ, US
Douglas Sutton - Parsippany NJ, US

International Classification:

A61F 9/00
A61K 9/00
A61K 31/19
A61K 31/407
A61K 31/4178
A61K 31/5377
A61K 31/5415
A61K 31/43
A61K 31/55
A61K 31/557
A61K 31/5575
A61K 31/56
A61K 31/568
A61K 31/573
A61K 31/58
A61K 31/7036
A61K 38/00
A61M 31/00
A61K 31/335

Abstract:

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

US Patent:

20200038240, Feb 6, 2020

Filed:

Oct 11, 2019

Appl. No.:

16/599828

Inventors:

- Madison NJ, US
Yair Alster - Madison NJ, US
Cary J. Reich - Madison NJ, US
K. Angela Macfarlane - Madison NJ, US
Janelle Chang - Madison NJ, US
Stephen Boyd - Madison NJ, US
David Sierra - Madison NJ, US
Jose D. Alejandro - Madison NJ, US
Douglas Sutton - Madison NJ, US
Alexander J. Gould - Madison NJ, US

International Classification:

A61F 9/00
A61L 27/16
A61L 27/02
A61B 17/00
A61K 9/00

Abstract:

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

US Patent:

20180177634, Jun 28, 2018

Filed:

Feb 26, 2018

Appl. No.:

15/905525

Inventors:

- Parsippany NJ, US
Yair Alster - Parsippany NJ, US
Cary J. Reich - Parsippany NJ, US
K. Angela Macfarlane - Parsippany NJ, US
Janelle Chang - Parsippany NJ, US
Stephen Boyd - Parsippany NJ, US
David Sierra - Parsippany NJ, US
Jose D. Alejandro - Parsippany NJ, US
Douglas Sutton - Parsippany NJ, US
Alexander J. Gould - Parsippany NJ, US

International Classification:

A61F 9/00
A61L 27/16
A61L 27/02
A61K 9/00
A61B 17/00

Abstract:

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.